Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 65.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,682 shares of the company's stock after acquiring an additional 45,222 shares during the period. Two Sigma Investments LP owned about 0.25% of Pacira BioSciences worth $2,161,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PCRX. China Universal Asset Management Co. Ltd. raised its position in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after acquiring an additional 918 shares in the last quarter. Caitlin John LLC increased its stake in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Empowered Funds LLC raised its holdings in Pacira BioSciences by 5.1% during the fourth quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock worth $4,323,000 after purchasing an additional 11,149 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Pacira BioSciences by 4.2% during the fourth quarter. Principal Financial Group Inc. now owns 257,733 shares of the company's stock worth $4,856,000 after purchasing an additional 10,306 shares in the last quarter. Finally, Ieq Capital LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter worth approximately $291,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Barclays lifted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Needham & Company LLC cut their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright boosted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences has an average rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX traded down $0.24 during midday trading on Thursday, reaching $26.74. 677,245 shares of the company were exchanged, compared to its average volume of 972,554. The stock has a market cap of $1.24 billion, a P/E ratio of -13.17 and a beta of 0.56. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $30.39. The stock has a fifty day simple moving average of $25.45 and a 200 day simple moving average of $23.19. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.